Dapirolizumab Pegol

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

13 Countries

Phase III

Phase III: 2

Indications tested

Systemic lupus erythematosus 2

Sponsors using this IMP

UCB Biopharma 2

All trials

2 total

A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting

2023-508191-11-00 Phase III 9 countries UCB Biopharma
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Phase III 13 countries UCB Biopharma

Showing 1–2 of 2 trials

← All drugs A–Z